Trial Profile
A pharmacokinetic study of Apixaban and Rosuvastatin in Nonalcoholic Fatty Liver Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jul 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Rosuvastatin (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Pharmacokinetics
- 05 Jun 2018 Results presented at the Digestive Disease Week 2018
- 27 Feb 2018 New trial record
- 22 Feb 2018 Results published in the Drug Metabolism and Disposition